Is Product Infatuation the Death Knell for Platforms?
Executive Summary
Incyte Genomics Inc., the creator of the database model and practically the ur-platform company, has suddenly decided to turn into a drug discovery company--changing top management to do so. Other firms that decided years ago to leverage genetic information to create drugs have far higher valuations than Incyte--indeed biotechs reporting product revenues get valuation multiples on sales that are twice as high as those platform companies command --and about triple the multiples that Big Pharma receives on its sales.
You may also be interested in...
For 2001, A Top Eleven List
2001 was a mixed year for health-care manufacturers, characterized by real advances in cardiac device therapies, the maturing of the biotech and generics sectors, and the continued embattlement of Big Pharma. Here's the staff of IN VIVO's list of the most important trends.
Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports